Cleveland-based biotechnology firm Athersys, Inc. is at the forefront of pioneering research and development activities in the field of regenerative medicine. The company's clinical development programs are dedicated to treating a wide range of conditions, including neurological conditions, cardiovascular diseases, and various inflammatory and immune disorders. Its MultiStem cell therapy, an allogeneic stem cell product, serves as the company's lead platform product, aiming to treat patients suffering from neurological damage caused by an ischemic stroke, acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. Additionally, the company has been developing MultiStem cell therapy to promote tissue repair and healing for animal patients. Athersys, Inc.'s license and collaboration agreements with Healios K.K. and the University of Minnesota have been instrumental in driving the development and commercialization of MultiStem cell therapy for various conditions, including ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as the treatment of liver, kidney, pancreas, and intestinal tissue diseases. The company's rich history dates back to 1995, and its mission to revolutionize regenerative medicine continues to be a source of hope for countless patients around the world.